Published in Curr Treat Options Psychiatry on September 01, 2015
Glutamate transport: a new bench to bedside mechanism for treating drug abuse. Int J Neuropsychopharmacol (2017) 0.75
Antidepressant effects of ketamine in depressed patients. Biol Psychiatry (2000) 10.91
Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry (2004) 5.26
Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature (2007) 4.59
Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci (2002) 4.52
The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry (2008) 3.81
Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry (2008) 3.63
Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res (2012) 3.31
Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell (2012) 3.22
D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry (2007) 3.03
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry (2006) 2.83
The burden of mental disorders. Epidemiol Rev (2008) 2.62
Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry (2007) 2.53
Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse. Nat Neurosci (2005) 2.31
Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry (2006) 2.23
Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. Arch Gen Psychiatry (2006) 2.02
Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry (2013) 1.92
A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol (2010) 1.86
Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res (2005) 1.73
Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther (2011) 1.71
Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci U S A (1998) 1.71
Genome-wide association study of obsessive-compulsive disorder. Mol Psychiatry (2012) 1.57
Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry (2005) 1.52
D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol (2007) 1.46
D-Cycloserine vs Placebo as Adjunct to Cognitive Behavioral Therapy for Obsessive-Compulsive Disorder and Interaction With Antidepressants: A Randomized Clinical Trial. JAMA Psychiatry (2015) 1.45
Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev (2008) 1.45
Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry (2000) 1.44
Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx (2006) 1.43
Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad Child Adolesc Psychiatry (2004) 1.41
Glutamatergic dysfunction in OCD. Neuropsychopharmacology (2005) 1.36
N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci (2011) 1.35
N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. J Am Acad Child Adolesc Psychiatry (2013) 1.32
N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl) (2005) 1.31
The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. Pharmacol Biochem Behav (2011) 1.29
Genome-wide association study in obsessive-compulsive disorder: results from the OCGAS. Mol Psychiatry (2014) 1.29
The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence. CNS Drugs (2012) 1.26
Riluzole in the treatment of mood and anxiety disorders. CNS Drugs (2008) 1.24
Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. Neurosci Biobehav Rev (2015) 1.21
Quality of life and functional impairment in obsessive-compulsive disorder: a comparison of patients with and without comorbidity, patients in remission, and healthy controls. Depress Anxiety (2009) 1.20
A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry (2010) 1.20
Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology (2013) 1.08
Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacol Bull (2009) 1.08
A critical review of magnetic resonance spectroscopy studies of obsessive-compulsive disorder. Biol Psychiatry (2012) 1.07
Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol Psychiatry (2012) 1.06
Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry (2010) 1.02
N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol (2012) 1.01
Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder. Neuropsychopharmacology (2009) 1.01
Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Psychopharmacol (2012) 0.99
Desensitization of the NMDA receptor complex by glycinergic ligands in cerebellar granule cell cultures. Brain Res (1993) 0.99
Glutamate as a neurotransmitter in the healthy brain. J Neural Transm (Vienna) (2014) 0.97
Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology (Berl) (2003) 0.97
Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis. PLoS One (2015) 0.97
Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder. Aust N Z J Psychiatry (2000) 0.95
Glutamatergic Synaptic Dysfunction and Obsessive-Compulsive Disorder. Curr Chem Genomics (2008) 0.95
Meta-analysis of association between obsessive-compulsive disorder and the 3' region of neuronal glutamate transporter gene SLC1A1. Am J Med Genet B Neuropsychiatr Genet (2013) 0.93
Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res (2012) 0.93
Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a series of 13 cases, with long-term follow-up. J Clin Psychopharmacol (2008) 0.93
A double-blind, placebo-controlled study of N-acetyl cysteine plus naltrexone for methamphetamine dependence. Eur Neuropsychopharmacol (2010) 0.93
Critical parameters for D-cycloserine enhancement of cognitive-behaviorial therapy for obsessive-compulsive disorder. Am J Psychiatry (2008) 0.92
Does D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis. PLoS One (2014) 0.90
12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder. Neuropsychopharmacology (2013) 0.89
Clinical predictors of health-related quality of life in obsessive-compulsive disorder. Compr Psychiatry (2009) 0.89
Topiramate Augmentation in Resistant OCD: A Double-Blind Placebo-Controlled Clinical Trial. CNS Spectr (2010) 0.87
Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry (2011) 0.87
Memantine as an augmenting agent for severe pediatric OCD. Am J Psychiatry (2009) 0.85
Pharmacological treatment of obsessive-compulsive disorder. Psychiatr Clin North Am (2014) 0.84
Modulation of NMDA receptor at the synapse: promising therapeutic interventions in disorders of the nervous system. Eur J Pharmacol (2013) 0.83
Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults. J Psychiatr Res (2008) 0.83
Glycine transporter type-1 and its inhibitors. Curr Med Chem (2006) 0.82
In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). Psychopharmacology (Berl) (2013) 0.82
Sarcosine therapy for obsessive compulsive disorder: a prospective, open-label study. J Clin Psychopharmacol (2011) 0.81
Isoforms of the neuronal glutamate transporter gene, SLC1A1/EAAC1, negatively modulate glutamate uptake: relevance to obsessive-compulsive disorder. Transl Psychiatry (2013) 0.81
Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial. J Clin Psychiatry (2015) 0.77
Ketamine-A Narrative Review of Its Uses in Medicine. Am J Ther (2015) 0.76